Suzhou Ribo Life Science

Suzhou Ribo Life Science (Ticker: 6938 HK) develops experimental RNA-based medicines, primarily small interfering RNA drugs, for cardiovascular, metabolic, kidney and liver diseases. Founded in 2007, the company is developing RBD4059, an experimental medicine designed to treat diseases involving harmful blood clots; it is in Phase 2 clinical trials. The company plans to use most of its IPO proceeds for research and development and to expand product capacity for its pipeline, with the remainder intended for working capital and strategic acquisitions.

The scheduled listing date on Hong Kong Stock Exchange was January 9, 2026. The proposed offering comprises 27,490,000 shares at an indicative price of HKD 57.97 per share. The base offering would represent HKD 1.59 billion, approximately $203.06 million in gross proceeds, excluding any unexercised over-allotment. The indicated IPO market capitalization is $1.20 billion.

CICC and Citigroup are joint sponsors.